Thermo and Cedar-Sinai Announce Collaboration
Thermo Fisher Scientific and Cedars-Sinai have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive LC–MS-based workflows for clinical research applications.
Thermo Fisher Scientific (Waltham, Massachusetts, USA) and Cedars-Sinai (Los Angeles, California, USA) have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive liquid chromatography–mass spectrometry (LC–MS)-based workflows for clinical research applications.
“Thermo Fisher shares our vision for helping clinical research teams set new standards for excellence and innovation in patient care through precision medicine. The goal is to develop advanced
LC–MSâbased workflows for the untargeted screening and targeted quantitation of protein-based biomarkers for critical disease states, which hold the potential to benefit not only our own patients but also the wider clinical community,” said Jennifer Van Eyk, Ph.D., Principal Investigator for Research and Director of the Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences at Cedars-Sinai.
For more information, please visit www.thermofisher.com/BeSure
An LC–HRMS Method for Separation and Identification of Hemoglobin Variant Subunits
March 6th 2025Researchers from Stanford University’s School of Medicine and Stanford Health Care report the development of a liquid chromatography high-resolution mass spectrometry (LC–HRMS) method for identifying hemoglobin (Hb) variants. The method can effectively separate several pairs of normal and variant Hb subunits with mass shifts of less than 1 Da and accurately identify them in intact-protein and top-down analyses.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
